IMW 2021 | The evolution of the myeloma treatment landscape
Jakub Radocha, PhD, of Charles University, Faculty of Medicine in Hradec Kralove, Prague, Czech Republic, shares his expectations of how the treatment algorithm for multiple myeloma will change and advance in the future. Dr Radocha suggests that combinations with monoclonal antibodies and current standard of care drugs will soon be the frontline treatment for patients with myeloma. Dr Radocha describes how chimeric antigen receptor T-cell (CAR-T) therapy may be implemented in earlier treatment lines and may replace autologous stem cell transplant. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Jakub Radocha, PhD, is a medical advisory board member for BMS, Janssen, GSK, Amgen and Sanofi; and has received travel expense reimbursement from BMS, Amgen and Sanofi.
